Exploring the synthesis and anticancer potential of L-tyrosine-platinum(II) hybrid molecules

Area of Science:

• Medicinal Chemistry
• Oncology
• Molecular Biology

Background:

• Chemotherapy often causes severe toxic side effects.
• Developing targeted cancer drugs with reduced toxicity is a key research area.
• Estrogen receptor alpha (ERα) is a target in hormone-dependent breast cancers.

Purpose of the Study:

• To design and synthesize novel non-steroidal-platinum(II) derivatives targeting ERα.
• To create compounds that deliver cytotoxic platinum to ERα-positive cancer cells without inducing estrogenic effects.
• To explore alternative synthetic routes for these platinum(II) hybrid molecules.

Main Methods:

• Modification of the amino acid L-tyrosine and attachment to a cisplatin analog.
• Development of three distinct synthetic methodologies for L-tyrosine-platinum(II) hybrids.
• Evaluation of preliminary biological activity on breast cancer cell lines.

Main Results:

• Three synthetic routes yielded the L-tyrosine-Pt(II) hybrid 5b with varying steps and overall yields (36%, 11%, 23%).
• The final hybrid compounds (5a and 5b) demonstrated no significant anticancer activity.
• The platinum(II) precursors (14a and 14b) exhibited biological activity comparable to cisplatin.

Conclusions:

• The designed L-tyrosine-platinum(II) hybrids were inactive against breast cancer cell lines.
• The platinum(II) precursors show promise as active chemotherapeutic agents.
• Further research into these platinum precursors could lead to more effective breast cancer treatments.